Using Induced Pluripotent Stem Cells to Characterize Cystic Fibrosis
Using Induced Pluripotent Stem Cells to Characterize Cystic Fibrosis
批准号:
10634647
负责人:
Ruobing Wang
金额:
$16.79万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-06-01 至 2026-05-31
关键词:
3-DimensionalAgonistAirArchivesAwardBasal CellBiological AssayBiological ModelsBiologyBostonCRISPR/Cas technologyCaringCaucasiansCellsChildhoodChloride ChannelsChloridesClinicalCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDefectDelta F508 mutationDerivation procedureDiseaseDisease modelDrug ModelingsElectrophysiology (science)EnvironmentEpithelial CellsEpitheliumEvaluationExhibitsFreezingFunctional disorderFutureGenesGeneticGenetic DiseasesGenetic PolymorphismGenotypeGoalsHumanIn VitroIndividualIon ChannelIonsLiquid substanceLung diseasesManuscriptsMeasuresMedicineMendelian disorderMentorsMentorshipModelingMucociliary ClearanceMucous body substanceMutationOrganoidsPatientsPediatric HospitalsPharmaceutical PreparationsPhenotypePhysiciansPluripotent Stem CellsPopulationPositioning AttributePreparationProtocols documentationRegenerative MedicineResearchResearch PersonnelRespiratory DiseaseRoleScientistSeverity of illnessSodium ChannelSystemTechniquesTestingTimeTrainingUniversitiesVariantVertebral columnViscosityairway epitheliumcandidate validationcareercareer developmentcystic fibrosis airway epitheliacystic fibrosis patientsdisease phenotypedrug discoveryepithelial Na+ channelexome sequencinggenetic variantimprovedin vitro Modelindividual patientindividual responseindividualized medicineinduced pluripotent stem cellinhibitorlung preservationmeetingsmembermolecular phenotypenovelpharmacologicprecision drugspulmonary functionpulmonary function declineresponsesingle-cell RNA sequencingstem cellstherapeutic candidatetherapeutic evaluationtimelinetool
中文摘要
项目摘要/摘要
该提案详细介绍了一个5年计划,以准备候选人,王若兵,医学博士,作为一个独立的职业生涯
医生-科学家定位于影响我们对儿科肺部疾病的理解,特别是囊性肺疾病
纤维化(CF)。作为一名照顾CF患者的临床医生,她发现了罕见的纯合子
符合临床入选标准的F508 del CFTR突变:1)CF长期非进展者(LTNP),
2)CF快速进展者(RP),其肺功能快速下降。全外显子组
测序揭示了i)SCNN 1(编码上皮钠通道)中罕见的错义多态性
ENaC),和ii)RP中上皮交替氯离子通道中的两个基因(ANO 1和SCL 26 A9)。的
该建议的中心假设是,CF的极端表型是由于
上皮细胞离子和液体运输由这些基因缺陷驱动,
严重性和机制可以用基于重编程细胞的平台在体外建模和研究。使用
一种新的方案,王博士从诱导多能干细胞(iPSC)中产生了气道基底样细胞,
然后在气液界面上分化为基底、多纤毛和分泌谱系,形成功能性的
具有完整屏障功能和异常跨上皮氯转运的气道上皮。正常化
通过CFTR基因编辑在这些细胞中的氯离子转运证实了她的模型重现CF的可靠性
表型。该项目的中心目标是建立这种用于CF疾病建模的新型iPSC平台
并研究极端表型患者的上皮功能。她现在正准备完成
目的是1)测试iPSC衍生的气道上皮细胞是否可以作为气道模型的平台
CF中上皮离子和液体转运以及粘膜纤毛转运,2)模拟极端表型CF患者
并询问候选修饰基因的作用及其对离子和液体转运的影响,以及3)
建立个性化药物反应的iPSC平台,并测试药理学的治疗作用
替代离子通道候选物的靶向。王医生有80%的时间不受波士顿儿童医院的保护
医院(BCH)呼吸系统疾病科和内科。她的共同赞助人是1)博士。
波士顿大学再生医学中心(CReM)的达雷尔·科顿(Darrell Kotton),
在过去的1.5年里接受了培训,2)Benjamin Raby博士,BCH呼吸系统疾病部门负责人。
此外,王博士还组建了一个由杰出的科学顾问组成的团队,
他们的具体专业知识,以协助她的职业发展和科学研究。详细的培训计划是
提出,包括指导研究,教学课程,在会议上介绍,和时间轴,
完成研究目标,准备手稿,以及未来的R 01应用。拟议
BCH和BU的研究、培训计划、指导委员会和科学-临床环境将
候选人在授标结束前过渡到独立。
英文摘要
Project Summary/Abstract
This proposal details a 5-yr plan to prepare the candidate, Ruobing Wang, MD, for a career as an independent
physician-scientist positioned to impact our understanding of pediatric lung diseases, particularly Cystic
Fibrosis (CF). As a clinician taking care of CF patients, she has identified rare individuals with homozygous
F508del CFTR mutations who met clinical criteria for inclusion as: 1) CF Long-term non-progressors (LTNP),
with preserved lung function 2) CF Rapid progressors (RP), whose lung function declines rapidly. Whole exome
sequencing uncovered rare missense polymorphisms in i) SCNN1 (which encodes epithelial sodium channel
ENaC) in LTNPs, and ii) two genes in epithelial alternative chloride channels (ANO1 and SCL26A9) in RPs. The
central hypothesis of the proposal is that the extreme phenotypes of CF are due to the alterations in
epithelial ion and fluid transport driven by these gene defects, and that the extreme-phenotype disease
severity and mechanism can be modeled and studied in vitro with a reprogrammed cell-based platform. Using
a novel protocol, Dr. Wang generated airway basal-like cells from induced pluripotent stem cells (iPSCs) which
can then differentiate into basal, multi-ciliated, and secretory lineages on air-liquid interface, forming a functioning
airway epithelium with intact barrier function and aberrant trans-epithelial chloride transport. Normalization of
chloride transport in these cells by CFTR gene editing confirms the reliability of her model to recapitulate CF
phenotype. The central goals of the project are to establish this novel iPSC-platform for CF disease modeling
and study the epithelial function of the extreme-phenotype patients. She is now uniquely poised to complete
the aims to 1) To test whether iPSC-derived airway epithelia can serve as a platform to model airway
epithelial ion and fluid transport and muco-ciliary transport in CF, 2) to model extreme-phenotype CF patient
and interrogate the role of candidate modifier genes and their impact on ion and fluid transport, and 3) To
establish the iPSC-platform for personalized drug response, and test the therapeutic role of pharmacologic
targeting of alternative ion channel candidates. Dr. Wang has 80% protected time from Boston Children's
Hospital (BCH) Division of Respiratory Diseases and the Department of Medicine. Her co-sponsors are 1) Dr.
Darrell Kotton at the Center for Regenerative Medicine (CReM) at Boston University (BU) with whom she has
trained for the past 1.5 years, and 2) Dr. Benjamin Raby, the chief of BCH Division of Respiratory Diseases.
Furthermore, Dr. Wang has assembled a team of extraordinary scientific advisory members, each bringing
their specific expertise, to assist her career development and scientific research. A detailed training plan is
presented that includes mentored research, didactic coursework, presentations at meetings, and a timeline for
completion of the research aims, preparation of manuscripts, and future R01 application. The proposed
research, training plan, mentorship committee, and scientific-clinical environment at BCH and BU will position
the candidate to transition to independence by the end of the award.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Using Induced Pluripotent Stem Cells to Characterize Cystic Fibrosis
-
批准号:10408667
-
项目类别:
-
资助金额:$16.79万
-
财政年份:2021
-
负责人:Ruobing Wang
-
依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: